Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study. Issue 9 (September 2022)

• Record Type: Journal Article
• Authors: Lee, Yeh Chen; King, Madeleine T.; O'Connell, Rachel L.; Lanceley, Anne; Joly, Florence; Hilpert, Felix; Davis, Alison; Roncolato, Felicia T.; Okamoto, Aikou; Bryce, Jane; Donnellan, Paul; Oza, Amit M.; Avall-Lundqvist, Elisabeth; Berek, Jonathan S.; Ledermann, Jonathan A.; Berton, Dominique; Sehouli, Jalid; Feeney, Amanda; Kaminsky, Marie-Christine; Diamante, Katrina; Stockler, Martin R.; Friedlander, Michael L.
• Is Part Of: Obstetrical & gynecological survey. Volume 77:Issue 9(2022)
• Page Start: 531
• Page End: 533
• Publication Date: 2022-09
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/OGX.0000000000001075
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Int J Gynecol Cancer 2022;32:761–768) Patients with recurrent ovarian cancer often experience a multitude of symptoms related to disease progression and the cumulative toxicities from multiple treatment regimens. The goals of chemotherapy in this context include palliating symptoms, improving health-related quality of life (HRQL), and delaying disease progression.